Adjuvant therapy using cytokine-induced killer cells are derived from peripheral blood mononuclear cells (PBMCs) of HCC patients and activated by IL-2 and anti-CD3 antibody. This evidence concerns the gene IL2 and hepatocellular carcinoma.